RECEIVED CENTRAL FAX CENTER

SEP 2 1 2005



Patent Technology Centers

Facsimile Transmission

To:

Name:

central fax

Company:

571-273-8300

Fax Number: Voice Phone:

From:

Name:

Official Fax Number:

(571) 273-8300

Official After Final Fax Number:

(571) 273-8300

Voice Phone:

37 C.F.R. 1.6 sets forth the types of correspondence that can be communicated to the Patent and Trademark Office via facsimile transmissions. Applicants are advised to use the certificate of facsimile transmission procedures when submitting a reply to a non-final or final Office action by facsimile (37 CFR 1.8(a)).

Fax	N	\nt	20	

Date and time of transmission: Wednesday, September 21, 2005 2:26:32 PM

Number of pages including this cover sheet: 08

USPTO TO:central fax

2005-Aug-29

COMPANY: 02:10 PM 9/21/2005 2:27 PM PAGE

2/008

Fax Server

Roche

ROCHE DIAGNOSTICS I

3175212883

1/7

iagnostics

Fax Cover Sheet

RECEIVED CENTRAL FAX CENTER

SEP 2 1 2005

To:

Examiner Taofiq A. Solola Fax

571-273-0709

Copies:

From:

Marilyn Amick

Roche Diagnostics Operations, Inc.

Tel.

(317) 521-7561 (317) 521-2883

Fax

(317) 521-2883

Date:

August 29, 2005

No. of pages:

(incl. cover sheet)

Re:

U.S. Application No.: 10/622,254

Filed:

July 18, 2003

Inventor(s):

Mitali Ghoshal et al.

Group Art Unit:

1626

Examiner:

Taofiq A. Solola

Atty Docket No.:

RDID02024US

AMENDMENT FOLLOWING ALLOWANCE

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

August 29, 2005

Date of Deposit Michele Wilson

Name of Person Mailing Correspondence

August 29, 2005

Date of Signature

2/7

COMPANY: 02:10 PM

ROCHE DIAGNOSTICS I

3175212883

RECEIVED CENTRAL FAX CENTER

SEP 2 1 2005

WEMHH/SB/21 (6/04)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE

Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB number. Application Number 10/622,254 TRANSMITTAL Filing Date July 18, 2003 **FORM** First Named Inventor Mitali GHOSHAL (to be used for all correspondence after initial filing) Art Unit 1626 **Examiner Name** Taofiq A. Solola 8 **RDID02024US** Total Number of Pages in This Submission Attorney Docket Number ENCLOSURES (Check all that apply) After Allowance communication to ☐ Fee Transmittal Form Drawings Group Appeal Communication to Board of П Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to Group Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Provisional After Allowance Proprietary Information Application Power of Attorney, Revocation ☐ Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please identify Extension of Time Request ☐ Terminal Disclaimer below); Express Abandonment Request Request for Refund CD, Number of CD(s) information Disclosure Statement Remarks Certified Copy of Priority Document(s) Response to Missing Parts/Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Marilyn L. Amlck Firm or Individual name Roche Diagnostics Operations, Inc. Signature Date August 29, 2005 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below Michele Wilson Typed or printed name Signature Date August 29, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTC to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTC. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800--PTO-9199 and select option 2.

USPTO 9/21/2005 2:27 PM PAGE 4/008 Fax Server

TO:central fax COMPANY: 2005-Aug-29 02:11 PM

ROCHE DIAGNOSTICS I

3175212883

3/7

RECEIVED CENTRAL FAX CENTER

Serial No. 10/622,254

SEP 2 1 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

GHOSHAL, Mitali et al.

Serial No:

10/622,254

Filed:

July 18, 2003

For:

ECSTASY-CLASS DERIVATIVES,

IMMUNOGENS, AND ANTIBODIES AND THEIR USE IN DETECTING ECSTASY-CLASS DRUGS

Art Unit:

1626

Examiner:

Taofiq A. Solola

AMENDMENT FOLLOWING ALLOWANCE

Mail Stop Non-Fee Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 August 29, 2005

RDID 02024

Dear Sir:

This amendment is being filed in response to the telephone message received by Applicants' representative on August 29, 2005 from Examiner Solola pointing out incomplete paragraphs in the specification that must be completed before the application can be sent to the printers.